Drug Trial Radar · NCT06197009
Efficacy and Safety of SCT650C in Participants With Axial Spondyloarthritis
Last checked: Nov 19, 2026Latest source record: Jan 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
168
Planned (sponsor's estimate)
Start
Jul 1, 2024
Primary completion
Jul 1, 2026
Study completion Aug 1, 2026
Sponsor
- Lead sponsor
- Sinocelltech Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SCT650C in patients with Axial Spondyloarthritis
Conditions
- Axial Spondyloarthritis
Interventions
SCT650CDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Axial Spondyloarthritis Reporting Adverse Events (AEs), Serious Adverse Events (SAEs), and Treatment Emergent Adverse Events (TEAEs)Time frame: 48 Weeks
- Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) ResponseTime frame: week 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hacettepe University Faculty of Medicine
Ankara, Hacettepe Mh., Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.